Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Flagrante Delictu who wrote (17956)	3/27/1998 10:01:00 AM
From: WTDEC	Read Replies (2) \| Respond to of 32384

"Anything else of interest in the report?" Bernie, sorry about the delay; I got a call from ML and signed off after the BS post. (:-}) Actually, there wasn't much more. Molowa was very pleased with the SKB leptin deal which prompted the one-page update. He sees the Panretin and Targretin NDAs as the main drivers of LGND stock price this year. His target is $25 at year-end. However, Henry need not worry about the wine. IMO, Dr. M is quite conservative. Regards, Walter